194 related articles for article (PubMed ID: 1647575)
1. Developments in foot-and-mouth disease vaccines.
Barteling SJ; Vreeswijk J
Vaccine; 1991 Feb; 9(2):75-88. PubMed ID: 1647575
[TBL] [Abstract][Full Text] [Related]
2. [Developments in foot-and-mouth disease (FMD) vaccine production (author's transl)].
Barteling SJ
Tijdschr Diergeneeskd; 1980 Sep; 105(17):695-8. PubMed ID: 6252656
[TBL] [Abstract][Full Text] [Related]
3. Development and performance of inactivated vaccines against foot and mouth disease.
Barteling SJ
Rev Sci Tech; 2002 Dec; 21(3):577-88. PubMed ID: 12523698
[TBL] [Abstract][Full Text] [Related]
4. Preparation of virus-infection-associated (VIA) antigen of foot-and-mouth disease (FMD) virus from inactivated vaccine.
Sugimura T; Tsuda T; Suzuki T; Murakami Y
J Vet Med Sci; 1996 Jun; 58(6):599-601. PubMed ID: 8811637
[TBL] [Abstract][Full Text] [Related]
5. Prospects for improved foot and mouth disease vaccines.
Doel TR
Vaccine; 1985 Mar; 3(1):35-6. PubMed ID: 2988225
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to foot and mouth disease vaccination.
Rowlands DJ
Vaccine; 1985 Mar; 3(1):37-9. PubMed ID: 2988226
[TBL] [Abstract][Full Text] [Related]
7. Synthetic peptide vaccines against foot and mouth disease.
Murdin AD
Vaccine; 1986 Dec; 4(4):210-1. PubMed ID: 3026104
[TBL] [Abstract][Full Text] [Related]
8. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination.
Lombard M; Füssel AE
Rev Sci Tech; 2007 Apr; 26(1):117-34. PubMed ID: 17633297
[TBL] [Abstract][Full Text] [Related]
9. International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them.
Doel TR; Pullen L
Vaccine; 1990 Oct; 8(5):473-8. PubMed ID: 2174597
[TBL] [Abstract][Full Text] [Related]
10. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen.
Sen AK; Saha SN
Acta Virol; 1994 Feb; 38(1):17-9. PubMed ID: 8067308
[TBL] [Abstract][Full Text] [Related]
11. Partial replacement of serum with peptone and lactalbumin hydrolysate for the production of foot-and-mouth disease vaccine in BHK-21 cells.
Saha SN; Sen AK
Acta Virol; 1989 Aug; 33(4):338-43. PubMed ID: 2574940
[TBL] [Abstract][Full Text] [Related]
12. Guinea pig protection test as indicator of potency of oil emulsion foot-and-mouth disease vaccines.
Black L; Pullen L; Boge A
Res Vet Sci; 1985 Sep; 39(2):207-11. PubMed ID: 2999930
[TBL] [Abstract][Full Text] [Related]
13. [Riems foot-and-mouth disease oil emulsion vaccines for swine. 2. Use of foot-and-mouth 2-component oil emulsion vaccines in practice].
Nöckler A; Thalmann G; Haack P; Nehmzow P; Poewe R; Pietzsch E; Seils G
Arch Exp Veterinarmed; 1990; 44(2):183-8. PubMed ID: 2167045
[TBL] [Abstract][Full Text] [Related]
14. Strategy for producing new foot-and-mouth disease vaccines that display complex epitopes.
McKenna TS; Rieder E; Lubroth J; Burrage T; Baxt B; Mason PW
J Biotechnol; 1996 Jan; 44(1-3):83-9. PubMed ID: 8717390
[TBL] [Abstract][Full Text] [Related]
15. Modified-live infectious bovine rhinotracheitis virus (IBRV) vaccine expressing foot-and-mouth disease virus (FMDV) capsid protein epitopes on surface of hybrid virus particles.
Kit S; Kit M; DiMarchi R; Little S; Gale C
Adv Exp Med Biol; 1991; 303():211-20. PubMed ID: 1725233
[No Abstract] [Full Text] [Related]
16. Proceedings: Quantitative assay of the immunizing dose of monovalent vaccines against foot-and-mouth disease prepared from the virus propagated on cattle tongue mucosa and in culture after Frenkel.
Wiśniewski J; Kobusiewicz T; Szkilnik S; Baranowski C; Jankowska J; Labecka W
Acta Microbiol Pol A; 1974; 6(1):131. PubMed ID: 4364054
[No Abstract] [Full Text] [Related]
17. Potency control of foot-and-mouth disease vaccine in cattle. Comparison of the 50% protective dose and the protection against generalization.
Vianna Filho YL; Astudillo V; Gomes I; Fernández G; Rozas CE; Ravison JA; Alonso A
Vaccine; 1993 Nov; 11(14):1424-8. PubMed ID: 8310761
[TBL] [Abstract][Full Text] [Related]
18. The use of cyclophosphamide as an enhancer of the vaccine against foot-and-mouth disease.
Portiansky EL; González PH; Laguens RP
Experientia; 1996 Jun; 52(6):605-7. PubMed ID: 8698098
[TBL] [Abstract][Full Text] [Related]
19. [The effectiveness of foot-and-mouth disease vaccines in Switzerland. II. Stability problems].
Ackermann M; Müller HK; Bruckner L; Kihm U
Schweiz Arch Tierheilkd; 1989; 131(7):389-95. PubMed ID: 2552580
[TBL] [Abstract][Full Text] [Related]
20. Efficiency testing of foot--and--mouth disease vaccines prepared from strain "C" with different adjuvants.
Sólyom F; Fazekas A; Czelleng F; Makár A; Roith J
Dev Biol Stand; 1976; 35():113-5. PubMed ID: 198276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
